Serotonin by DOROTEA MÜCK-ŠELER & NELA PIVAC
Serotonin
Abstract
Serotonin is a monoamine that could be found in plans, animals and hu-
man body. The homeostasis of serotonin is maintained by the series of inter-
dependent processes that include synthesis, storage, transport and removal/
degradation. In the human body serotonin is synthesized in two independ-
ent compartments that are separated by brain-blood barrier. The majority of
serotonin is synthesized in enterochromaffin cells of the gastrointestinal
tract, released in the blood stream and stored in blood platelets. About 5% of
serotonin is synthesized in the brain within serotonergic neurons. As a neu-
rotransmitter serotonin plays an important role in the regulation of physio-
logical functions like body temperature, sleep, vomiting, sexuality, appetite,
behaviour and cognitive functions such as learning and memory. The dys-
function of the serotonergic system has been implicated in the aetiology of a
variety of psychiatric (depression, schizophrenia, alcoholism) and neurolog-
ical (migraine, Alzheimer’s disease, epilepsy) disorders. Recent genetic asso-
ciation studies of the neuropsychiatric disorders have focused on functional
polymorphisms i.e. DNA sequence variations that alter the expression and/
or functioning of the gene product in the loci encoding different genes.
Some of them are genes for tryptophan hydroxylase, serotonin transporter
and serotonergic receptors.
THE BEGINNINGS
Serotonin (5-hydroxytryptamine, 5-HT) was discovered 60 years agoin blood, peripheral tissues and central nervous system (1). It was
first identified as a vasoconstrictor substance that is released from plate-
lets during the coagulation of blood, and later as a monoamine neuro-
transmitter in the brain. It has been established that gastrointestinal
tract, blood platelets and brain were the main locations of serotonin in
the mammal’s body. In addition, serotonin could be also found in plants
(bananas, walnuts, tomatoes, hickories, pineapples), mushrooms, octo-
puses, and in poison of insects (spiders, scorpions, wasps).
Synthesis and metabolism
Serotonin is a tryptamine that consists of an indole ring with a hydro-
xide group on the fifth C atom, and a carboxyl-amide side chain (Figure 1).
The main precursor of serotonin is the essential amino acid L-try-
ptophan that must be provided by food. L-tryptophan and the other
precursor, 5-hydroxytryptophan, are transported from blood to brain by
the active carrier system located in the blood-brain barrier (BBB). It is
believed that serotonin, due to its chemical properties, does not cross
BBB, but new evidence (2) suggests that serotonin might cross endo-
thelial cells of the BBB using serotonin transporter. The serotonin syn-
thesis occurs in a two-step enzymatic procedure (Figure 2). The first
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and rate-limited step is hydroxylation of the tryptophan
to 5-hydroxytryptophan. This reaction is catalyzed by
tryptophan hydroxylase, a specific enzyme located only
in the serotonergic neurons (3). The 5-hydroxytrypto-
phan is decarboxylated by a nonspecific enzyme, aro-
matic amino acid decarboxylase, into serotonin. Seroto-
nin levels could be determined in the brain and various
body fluids including serum/plasma, platelets, cerebro-
spinal fluid (CSF) and urine. The flavine-containing
mitochondrial enzyme monoamine oxidase (MAO) is
the most important enzyme for degradation of serotonin.
This process has two steps: first step is a degradation of
serotonin into 5-hydroxyindole acetaldehyde, and the
second one is degradation through aldehyde dehydro-
genase regulated conversion into 5-hydroxyinoleacetic
acid (5-HIAA) as the main metabolite of serotonin.
In the human body, serotonin is synthesized and lo-
cated in two compartments that are separated by BBB.
The first compartment, called »peripheral« compartment,
contains the majority (about 95%) of serotonin in the
body. Peripheral serotonin is synthesized in enterochro-
maffin cells of the gastrointestinal tract. The second, i.e.
»central« compartment of serotonin is the central nervous
system that synthesizes serotonin within serotonergic
neurons. Recent studies (3, 4) revealed that tryptophan
hydroxylase exists in two isoforms with different location
within the body of mammals (Table 2). Tryptophan hy-
droxylase type 1 (TPH1) is responsible for the synthesis
of the peripheral serotonin (4), while tryptophan hy-
droxylase type 2 (TPH2) is the predominant isoform in
the brain.
Serotonergic receptors
The complex functions of serotonergic system would
be impossible without a large number of serotonergic re-
ceptors (5). Serotonergic receptors are classified in seven
different groups or »families« called 5-HT1, 5-HT2,
5-HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7, and several
subtypes (Table 1) that differ in terms of structure, ac-
tion, and location. Serotonergic receptors are distributed
on the presynaptic and postsynaptic neurons in the cen-
tral nervous system and on the different peripheral cells
and organs (Table 1). The majority of serotonin receptors
are G protein-coupled receptors. The exception is 5-HT3
receptor that belongs to the ligand-gated ion channel re-
ceptors. Serotonergic receptors activate an intracellular
second messenger (cAMP, IP3, DAG) cascade and pro-
duce an excitatory or inhibitory response. Serotonin re-
ceptors are very important sites of action for different
classes of psychotropic drugs, like antidepressant drugs
(5), atypical antipsychotic drugs (olanzapine, risperidone)
and psychoactive compounds (LSD, DMT).
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Figure 1. The chemical structure of serotonin or 3-(2-aminoet-
hyl)-5-hydroxyindole.
Figure 2. Synthesis and degradation of serotonin.
TABLE 1
The serotonergic receptors.
Type Subtype Distribution Intracellular response
5-HT-1 1A, 1B, 1D, 1E, 1F CNS, blood vessels Inhibitory
5-HT-2 2A, 2B, 2C CNS, platelets, blood vessels, smooth muscle Excitatory




5-HT-7 CNS, GI tract, blood vessels Excitatory
Serotonin in the central nervous system
Serotonergic neurons are widely distributed through-
out the mammalian brain and serotonergic system is the
largest single system in the brain. The nine groups of
serotonergic cell bodies are located mainly in the area of
brain stem raphe nuclei. Serotonergic nerve terminals
could be found in nearly all other regions of the central
nervous system. The widespread distribution of the ra-
phe projections suggests a highly collateralized axon sys-
tem (6). The communication of serotonergic system with
other important neurotransmitter systems like catechola-
minergic system (7) is well established, although the
mechanisms of interaction are not yet completely under-
stood. Significant amounts of data have demonstrated
that these interactions are very important in the mecha-
nisms of action of antidepressant and anxiolytic drugs.
Serotonin is implicated in many physiological (body
temperature, sleep, vomiting, sexuality, appetite), behav-
ioural (aggression, mood) and cognitive (learning, mem-
ory) functions (8). In addition, serotonin has an impor-
tant role in the growth of the central nervous system
during development. It plays a critical role as a growth
factor in the immature brain, directing both proliferation
and maturation. This is supported by the higher seroto-
nin turnover rate in the immature mammalian brain
than at any other time in life. Recent data (9) suggested
that an overload of serotonin during cortical develop-
ment could induce abnormal distribution and incorrect
positioning of cortical interneurons.
There are several methods for the determination of se-
rotonin synthesis rate in vivo: a) pharmacological ma-
nipulation, i.e. after the administration of compound
that inhibits enzyme aromatic acid decarboxylase like
NSD-1015, b) the use of radiolabel tryptophan, c) the
use of radiolabel alpha-methyl tryptophan (alpha-MTrp)
as an analogue of tryptophan. The limitation of the
pharmacological methods is that the effect of the tested
compound on the serotonin synthesis could be in part in-
fluenced by the pre-pharmacological manipulation it-
self. Radiolabel tryptophan is an essential amino acid in-
corporated in proteins, while radiolabel tryptophan me-
tabolites, like serotonin and 5-HIAA, are lost very rap-
idly from the brain. The use of alpha-MTrp labelled with
3H or 14C and the determination of serotonin synthesis
by an autoradiographic method (10) permits the mea-
surement of serotonin synthesis in the rat brain with high
anatomical resolution and without any pharmacological
pre-treatment. The disadvantages of this method are the
need for special equipment and a long procedure.
The alteration of the serotonergic system has been re-
lated with the aetiology of different neurological (mi-
graine, Alzheimer’s disease, epilepsy) and psychiatric
(depression, schizophrenia, mood disorders, alcoholism,
ADHD, PTSD) disorders.
Peripheral serotonin
Peripheral serotonin is synthesized in enterochroma-
ffin cells of the gastrointestinal tract. The synthesis is reg-
ulated by TPH1 (4). From gut serotonin is released in the
blood stream and than stored mostly in blood platelets.
The other peripheral cells that contain serotonin are
macrophages and mast cells. Peripheral serotonin is me-
tabolized in the liver by a MAO-A to 5-HIAA. The
5-HIAA is filtrated and excreted by the kidney. The vast
increase in urine excretion of 5-HIAA was found in
carcinoid syndrome, due to the pronounced production
of serotonin by carcinoid cells.
In humans a direct association between neurotrans-
mitters in the brain and those excreted in the urine is not
yet defined. New evidence suggests (2) that neurotrans-
mitters excretion in the urine might be used as possible
biomarkers of the central nervous system activity. The
study in rats treated with 5-hydroxytryptophan has shown
simultaneous changes in the activity of brain seroto-
nergic system and urinary serotonin levels.
Serotonin has an important role in the vascular biol-
ogy. It is involved in the control of vascular resistance,
blood pressure, haemostasis and platelet function (11).
One of the most important functions of the peripheral se-
rotonin is the promotion of platelet aggregation and
blood clotting. Activated 5-HT-2A receptors on platelet
membrane also stimulate platelet activation and aggre-
gation.
Blood platelets and serotonergic
neurons
The function of central serotonin in mood, state of
mind, and behaviour, as well as its role in cognition and
memory are very difficult to establish. Literature data
suggest that blood platelets can be used as an easy obtain-
able peripheral model for the some processes in the cen-
tral serotonergic neurons (12–14) (Table 2). The kinetic
and pharmacological characteristics of the active trans-
port of serotonin from plasma to platelets are similar to
the reuptake of serotonin from synaptic cleft into pre-
synaptic neurons. In addition, platelet MAO type B ac-
tivity corresponds to MAO-B activity in presynaptic part
of neurons. There are also 5-HT2A receptors (14), a2-adre-
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TABLE 2
Similarities and differences between blood platelets and
serotonergic synaptosomes.
Brain serotonergic neuron Blood platelets
Similarities
Serotonin stored in dense bodies or vesicles
Active transport (uptake) of serotonin
Binding sites for 3H-paroxetine, 3H-imipramine
Receptors: 5-HT2A and a2-adrenergic
Monoamine oxidase type B
Differences





nergic receptors (15) and binding sites for 3H-imiprami-
ne and 3H-paroxetine on the platelet membrane, which
can be used as peripheral markers for the evaluation of
pharmacologic and kinetic characteristics of equivalent
central nervous receptors and binding sites on presynap-
tic or postsynaptic part of the serotonergic neurons in
psychiatric and neurodegenerative disorders.
Numerous studies have tested platelet serotonin con-
centrations in various psychiatric disorders. Altered pla-
telet serotonin concentrations were found in patients
with different psychiatric and neurological disorders like
major depression (16), subtype of major depression with
psychotic symptoms (17), bipolar disorder (18), schizo-
phrenia (16, 19–21), postpartum depression (22), post-
traumatic stress disorders (PTSD) with comorbid depre-
ssion (23), PTSD with psychotic symptoms (24), alcohol-
ism (25), attention-deficit/hyperactivity disorder (ADHD)
with impulsive symptoms (26), migraine (27), and Alz-
heimer’s disease (28, 29).
SEROTONIN AND NEUROPSYCHIATRIC
DISORDERS
Preclinical and clinical investigations suggest that se-
rotonin could be related to the aetiology and treatment of
different neuropsychiatric disorders including depres-
sion, schizophrenia, PTSD, alcoholism, ADHD and Alz-
heimer’s disease (AD).
Depression
Depression is a severe and devastating mental disor-
der with a high prevalence worldwide, and with twice
higher risk in women than in men. Although, the patho-
genesis and treatment of depression were the topics of in-
tensive preclinical and clinical research, the complex
neurobiological basis of depression is still unclear (30).
The first hypothesis of depression was established almost
forty years ago (31). It postulated that depression is a
consequence of the low serotonin and/or noradrenalin
levels and the dysfunction in the central serotonergic,
noradrenergic and dopaminergic systems. These neuro-
transmitters interact with each other and regulate mood,
sleep, anhedonia, appetite, concentration and motiva-
tion, suicidal behaviour, cognitive and autonomic func-
tions (8) that are frequently disturbed in depression.
In following years numerous attempts were made to
identify the reproducible neurochemical alterations in
the nervous systems of patients with depression, but
mostly with negative or inconsistent results. Concentra-
tions of 5-HIAA, the major 5-HT metabolite, in CSF
have been extensively studied in depressed subjects. A
significant reduction in CSF 5-HIAA was found in de-
pressed patients (32), but several other studies (33) were
not able to confirm the difference in 5-HIAA levels be-
tween depressed patients and healthy controls. Recent
study (34) described elevated brain serotonin turnover
rate in medication-free patients with depression, particu-
larly in those carrying the short form (s allele) of the gene
for serotonin transporter. However it was not clear if the
elevated brain serotonin turnover is a consequence of in-
creased neuronal activity, enhanced vesicular leakage and
subsequent intraneuronal metabolism or reduced brain
serotonin transporter availability.
Platelet serotonin levels, platelet 5-HTT and platelet
5-HT2A receptors were also investigated in depression.
The decreased (35) or unaltered (19, 36) platelet seroto-
nin levels were found in depressive patients as well as alte-
red number of platelet 5-HT2A receptors and the num-
ber of platelet serotonin uptake sites (37).
The majority of antidepressant drugs in current use,
act by affecting the neurotransmitters (serotonin, norad-
renalin, and dopamine), their receptors and enzymes in-
volved in their synthesis or degradation (38). However,
the clinical improvement after antidepressant therapy is
usually observed 2–3 weeks after the beginning of the
treatment. It is believed that this therapeutic delay de-
pends on the antidepressant-induced desensitization of
serotonergic or noradrenergic receptors.
Schizophrenia
Schizophrenia is a complex and multifactorial mental
disorder with the prevalence of 1% worldwide. The alter-
ations of the dopaminergic system and their receptors are
the basis for the »dopaminergic hypothesis« of schizo-
phrenia. Since this hypothesis is not able to explain the
complex symptoms of disease and efficacy of atypical
antipsychotics, with a higher affinity for 5-HT2A than to
D2 receptors, it is supposed that schizophrenia might be
associated with the dysfunction of other neurotransmit-
ters systems like serotonergic system (39). In addition
serotonergic system regulates some physiological and be-
havioural functions that are disturbed in schizophrenia
(8). In line with this »serotonin hypothesis of schizo-
phrenia« the alteration of serotonergic activity was found
in the brain of schizophrenic patients, with the decreased
serotonin neurotransmission in cortical regions, and in-
creased in the putamen, accumbens and pallidus. The
decreased or unaltered density of 5-HT2 receptors in
frontal cortex (39), decreased density of 5-HT1A recep-
tors and unchanged 5-HT6 receptor binding (40) were
also found in schizophrenic patients.
An increase in platelet serotonin concentration was
observed in schizophrenic patients with predominantly
chronic time course (41), with paranoid symptoms (19),
positive symptoms (42) and in schizophrenic patients
born in winter (20). Although there is no direct evidence
that platelets serotonin concentration correlates with cen-
tral serotonin levels, an abnormal tomographic brain
scans were found in schizophrenic patients with high
platelet serotonin levels (43).
Posttraumatic stress disorder
Posttraumatic stress disorder (PTSD) is a severe psy-
chiatric and polygenetic disease that appears in some
people that survived the extremely dangerous traumatic
life event like natural disasters, war or sexual abuse.
PTSD could be associated with alterations in different
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neuroendocrine (44) and neurotransmitter (45) systems.
Despite the intensive neurobiological research, the role
of serotonin in the pathophysiology of PTSD is still un-
clear. Some studies (46) suggested altered serotonergic
function in PTSD that might contribute to cognitive dis-
turbances, depressive symptoms and many physiological
and pathological behaviours, such as aggression, that fre-
quently arises in PTSD.
It is believed that serotonergic neurons from dorsal
nuclei raphe with nerve terminals in hippocampus and
amygdala are responsible for anxiogenic response to stress
via 5-HT2A receptors, while neurons from median ra-
phe have anxyolitic effect achieved through 5-HT1A re-
ceptors. However, a positron emission tomography study
(47) did not find altered 5-HT1A receptors binding in
patients with PTSD compared to healthy subjects. Indi-
rect peripheral evidences for the altered efficacy of sero-
tonergic system in PTSD are decreased serum serotonin
concentration and altered number of platelet serotonin
transporters (48). Platelet serotonin concentration was
higher in PTSD veterans with psychotic subtype of PTSD
compared to platelet serotonin concentration in non-
-psychotic war veterans or in healthy controls (24). Since
platelet serotonin concentrations correlated with the se-
verity of delusions, the core psychotic symptoms, these
data confirmed that platelet serotonin concentration might
be used as a trait marker of psychotic symptoms in PTSD.
Alcoholism
Literature data suggest that alcohol dependence and
alcohol abuse could be associated with the disturbance in
serotonergic system (49). The role of serotonin in alco-
holism is based on the data showing alterations in mea-
sures of the serotonergic function in the brain, as well as
in CSF, blood precursor availability, uptake of serotonin
in blood platelets and challenge studies.
Post-mortem brain analyses have found reduced sero-
tonin transporter binding in the hippocampus (50) or in
dorsal striatum (51), and decreased density of 5-HT1A
receptors (52) in patients with alcoholism compared to
non-alcoholic controls. Reduce activity of serotonergic
transporter in the brain of abstinent alcoholics was con-
firmed in vivo using SPECT (53). The values of 5-HIAA
concentration in CSF are in line with central seroto-
nergic disturbances in patients with alcoholism. Low
levels of 5-HIAA in CSF were found in early-onset alco-
holics (54), in abstinent alcoholics (55) and in alcoholic
impulsive offenders (56).
Decreased plasma tryptophan levels and low seroto-
nin precursor availability suggest impaired serotonin syn-
thesis in alcoholism (49). The results on the blood plate-
lets serotonin transporter activity in patients with alco-
holism are inconsistent. Lower (57), increased (58), or un-
altered (59) serotonin uptake into platelets were found in
alcoholics when compared to healthy controls. Alcohol-
ism-induced fall of serotonin transporter activity has been
related to a decreased platelet serotonin content observed
in male and female alcoholic patients, independently on
the presence of comorbid psychiatric disorders (60).
It has been shown that prolactin or cortisol response
to administration of serotonergic drugs like fenflurami-
ne, m-clorophenylpiperazine, 6-chloro-2-1-piperazinyl-
pyrazine, and adrenocorticotropic hormone (ACTH) re-
sponse to m-chlorophenylpiperazine, was lower in alco-
holics than in non-alcoholic patients (61), suggesting
also altered central serotonergic function in alcoholism.
ADHD
Serotonin dysfunction has been implicated also in
ADHD, although the primary neurotransmitter that is
altered in ADHD is dopamine, and to a lesser extent,
noradrenalin (62). However, besides the classical charac-
teristics symptoms of ADHD (such as hyperactivity, inat-
tention and impulsivity), aggression, as well as distur-
bances in the cognition, are also frequent in ADHD.
These findings confirmed also the role of serotonin in
ADHD (63). The concentration of serotonin was found to
be lower in ADHD (64), or unaltered in ADHD (26).
Since ADHD is a multifactorial and clinically heteroge-
neous psychiatric disorder, platelet serotonin concentra-
tion was found to be increased in children with ADHD
with pronounced impulsive symptoms (26) suggesting
that higher platelet serotonin concentration in impulsive
compared to non-impulsive children with ADHD might
be used as a possible trait marker of impulsivity in ADHD.
The impulsivity is associated with serotonin function in
non-clinical sample (65). There is a significant correla-
tion between impulsivity and lower serotonergic func-
tion (66). On the other hand, the opposite data exist, and
therefore impulsivity has been associated also with the
increased serotonergic functioning (67) in children and
adolescents.
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative dis-
order characterized with a progressive loss of cognitive
functions such as learning and memory. The aetiology
and pathophysiology of AD is still unclear. The neuro-
biological alterations in AD include accumulations of
amyloid plagues outside and neurofibrillary tangles in-
side neurons and the dysfunctions of cholinergic, cate-
cholaminergic and serotonergic systems. The decrease in
the brain concentration of serotonin and 5-HIAA was
found in AD (68). The loss of presynaptic somatoden-
dritic 5-HT1A autoreceptors and postsynaptic 5-HT1A
heteroreceptors (68), and 5-HT2 receptors in cerebral
cortex (69), were also found in patients with AD. It seems
that the development of behavioural and psychological
symptoms in AD (70) is related to the genetic variants of
5-HT2A and 5-HT2C receptors. In addition, daily living
and functioning was improved in patients with AD trea-
ted with combination of rivastigmine and selective sero-
tonin reuptake inhibitor, fluoxetine.
The reduced serotonin concentration in platelets (29),
CSF (71) and brain (72) of patients with AD would sug-
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gest the decrease in serotonin synthesis. The main factors
that influence serotonin synthesis are plasma availability
of its precursor tryptophan and the activity of the rate-
-limiting enzyme TPH. Plasma level of tryptophan de-
pends on the dietary intake and feeding behaviour that
could be also changed in AD. In patients with AD low
tryptophan concentrations in serum (73), plasma (74)
and CSF (71) was found in some, but not all studies (75).
The alterations in serotonergic and kynuramine path-
ways of tryptophan metabolism have been connected to
pathophysiology of AD (76), suggesting that low plasma
tryptophan concentration in AD might be also a conse-
quence of the enhanced tryptophan degradation via the
kynuramine pathway (73). In addition, tryptophan de-
pletion in healthy volunteers (77) or in patients with
mild to moderate AD (78) induced changes in cognitive
performance.
Altered serotonin synthesis in AD (72) might be a
consequence of reduced TPH activity in particular brain
areas of patients with AD (79) or the lack of the TPH co-
factors tetrahydrobiopterin and folic acid. Since TPH ac-
tivity is sensitive to reactive oxygen species, the tetrahy-
drobiopterin deficiency could also impair serotonin syn-
thesis through oxidative damage of TPH (80).
A decreased platelet serotonin concentration observed
in patients with AD in the late phase of disease (29),
might be related to the reduced serotonin active transport
through platelet membrane. This finding is in line with
the decrease in the maximum number (Vmax) of seroto-
nin transporters found in severely ill patients with AD
compared to both patients with mild AD and healthy
controls (81).
CANDIDATE GENES OF THE
SEROTONERGIC SYSTEM
Recent genetic association studies of the neuropsychi-
atric disorders have focused on functional polymorphi-
sms i.e. DNA sequence variations that alter the expres-
sion and/or functioning of the gene product in the loci
encoding different genes. Some of them are genes for
TPH, serotonin transporter (5-HTT) and serotonin type
1A (5-HT1A), 1B (5-HT1B), 2A (5HTR2A) receptors.
Tryptophan hydroxylase
Tryptophan hydroxylase (EC 1.14.16.4) is a key en-
zyme in the synthesis of serotonin. It metabolizes the es-
sential amino acid L-tryptophan, by hydroxylation at the
position 5, to the serotonin precursor L-5-hydroxytryp-
tophan (Figure 3.). The cofactors are O2 (dioxygen), BH4
/(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin/ and Fe2+.
TPH is a specific and selective enzyme that is only lo-
cated in the serotonin producing cells like serotonergic
neurons, pineal gland and enterocromaffine cells of the
gut. It exists in two isoforms (3), with different location
within the body of mammals (Table 3). One isoform is
TPH1 that is responsible for the synthesis of the periph-
eral serotonin (4), while TPH2 is the predominant iso-
form in the brain.
In humans, the genes for TPH1 (MIM *191060) and
TPH2 (MIM *607478) are located on chromosomes 11
at position 11p14-p15.3 and 12 (12q21), respectively. The
human TPH2 gene spans 97 kilobases (kb) and consists
of 11 exons. The sequence identity between two homolo-
gous TPH is 71% (121). In TPH1 knockout mice the
concentration of peripheral serotonin was reduced to 6%
(blood), 1.5% (jejunum) and 0.1% (colon) as compared
to serotonin concentration in wild type mice (3, 82).
However, genetically modified mice without TPH1 iso-
form had normal serotonin concentration in hippocam-
pus and frontal cortex (82), and similar development, ap-
pearance and behaviour as mice with TPH1 gene. Those
results suggested that serotonin synthesis in the brain de-
pends mostly on the TPH2 isoform activity. Recently,
Savelieva et al. (3) reported the phenotypic evaluation of
TPH2 knockout mice and double knockout mice with-
out both TPH1 and TPH2 gene. They have found the
pronounced decrease in serotonin levels in cortex, thala-
mus/hypothalamus, olfactory bulb, cerebellum hippo-
campus, brainstem and striatum in both groups of kno-
ckout mice compared to wild type mice. The lowest
serotonin concentration was determined in double kno-
ckout mice without TPH1 and TPH2 gene. Although
genetically modified mice were similar in appearance, or
histological analysis with no loss of the serotonergic cell
bodies in raphe nucleus, there were differences in the
body weight, body size and percent of body fat in male,
and percent of body fat in female double knockout mice
compared to wild type mice (3). There were a few effects
of TPH genotype on behaviour. Mutant mice had similar
exploratory behaviour and locomotor activity and sho-
wed increased anxiety-like behaviour (3).
Several studies analyzed the association between ge-
netic variants of the TPH in neuropsychiatric disorders
and emotion-related personality traits, but with inconsis-
tent results. Zhang et al. (83) reported that allele A of the
functional polymorphism G1463A at TPH2 gene could
34 Period biol, Vol 113, No 1, 2011.
Dorotea Mück-[eler and Nela Pivac Serotonin






Figure 3. Tryptophan hydroxylase catalyzes tryptophan to 5-hydroxy-
tryptophan.
be related to the low TPH2 activity and consequently to
the impaired brain serotonin synthesis in depressed pa-
tients. Their suggestion that 1463A allele could be a risk
factor for unipolar major depression were not confirmed
in the larger number of patients of the West European
Caucasian origin with affective disorders (84), or in Chi-
nese population with unipolar depression (85). Recent,
haplotype analysis of the eight polymorphisms: rs4448731
(intergenic), rs4565946 (intron 2), rs11179000 (intron 4),
rs7955501 (intron 5), rs10506645 (intron 7), rs4760820
(intron 8), rs1487275 (intron 8) and rs10879357 (intron
8) of the human TPH2 (86) has shown no association
between TPH2 polymorphisms and bipolar depression
and suicidal behaviour in Brazilian population. There
were also no significant differences in genotype or allele
frequencies of the TPH2 -703G/T polymorphism be-
tween bipolar patients and healthy subjects of the Ko-
rean origin (87). The meta-analysis of TPH1 and TPH2
gene variants in the large number of subjects with ADHD
from four independent European Caucasian samples
have shown no consistent evidence for common genetic
variants in the TPH1 and TPH2 regions in ADHD (88).
It has been hypothesized that smaller volumes of the
amygdala and hippocampus are related to the presence
of the T allele of the TPH2 (rs4570625; G-703T) poly-
morphism in Japanese subjects. This was the first study
that compared personality traits (harm avoidance, re-
ward dependence, novelty seeking, persistence, self di-
rectedness, cooperativeness, self-transcendence) assessed
with the Temperamental and Character Inventory (89),
with the volume of amygdala and hippocampus (deter-
mined using magnetic resonance imaging) in T allele
carriers and GG individuals. The results suggested that
regional brain volume could be a brain structural inter-
mediate phenotype between genetic variations in THP2,
i.e. between serotonin synthesis and personality traits re-
lated to mood or anxiety disorders (89).
Serotonin Transporter-Linked
Polymorphic Region
The serotonin transporter (5-HTT) is an important
protein responsible for the active transport of serotonin
into neurons, enterochromaffin cells and platelets. In the
brain 5-HTT is localized in membrane of presynaptic
nerve terminals and in dendritic arbors close to seroto-
ninergic cell bodies. 5-HTT regulates serotonin levels in
the synaptic cleft following neuronal stimulation, and
consequently the magnitude and duration of its effect on
postsynaptic serotonergic receptors. It terminates the ac-
tion of serotonin by rapid reuptake of released serotonin
from synaptic cleft into presynaptic neuron by means of
an active transport process that depends upon maintenance
of ion gradients across the cell membrane by Na+-K+-
–ATPase (90). The in vitro and in vivo (91) studies have
shown that 5-HTT is not only a protein with important
role in the homeostatic regulation of the serotonergic
function, but also a site of action for several classes of an-
tidepressant drugs including classical tricycle compounds
and novel selective serotonin reuptake inhibitors (91).
Among a number of genes involved in the synthesis of
protein related to metabolism and function of serotoner-
gic system, gene encoding the 5-HTT (SLC6A4) is the
most extensively investigated. The 5-HTT gene (OMIM
*182138) is located on chromosome 17 at position 17q11.1-
-17q12 and consisted of fifteen axons encoding a protein
of 630 amino acids with 12 transmembrane domains (90,
92). The most studied variants in the 5-HTT gene are the
serotonin transporter-linked polymorphic region (5-HTT
gene-linked polymorphic region, 5-HTTLPR; rs795541)
and a functional variable number of tandem repeats
(VNTR) polymorphism in intron 2. 5HTTLPR is a re-
petitive element of varying length in the 5’ flanking re-
gion located ~1.4kb upstream of the transcription start
site that modulates transcriptional activity of human 5-
-HTT (90). A deletion/insertion in the 5-HTTLPR cre-
ates two alleles (each of 20 to 23 bp): short or S allele and
long or L allele made up of fourteen and sixteen repeated
elements, respectively. Some studies have found that long
allele results in higher serotonin transporter mRNA tran-
scription in human cell lines. The uptake of serotonin is
two-fold higher in cells containing the homozygous L/L
form of the SLC6A4 than either the L/S or S/S forms. On
the other hand, S allele is associated with reduced trans-
criptional efficiency and decreased 5-HT expression and
uptake (92).
It has been suggested that this 5-HTTLPR polymor-
phism alters the promoter activity and consequently se-
rotonergic functions (93). In this respect, a significantly
higher maximal number (Bmax) of platelet serotonin
uptake sites was found in subjects carrying the L/L geno-
type as compared with Bmax of platelet serotonin uptake
sites in individuals with L/S or S/S genotype (94). Addi-
tionally, the uptake of serotonin is approximately two-
-fold higher in cells containing the homozygous L/L
form of the 5-HTT, while S allele is related to reduced
transcriptional efficiency and therefore decreased seroto-
nin uptake (92). Volumetric neuroimaging studies have
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TABLE 3
Two tryptophan hydroxylase isoforms, their location











Intestinal motility Food intake and body weight
Melatonin synthesis Neuropsychiatric disorders
shown that the S allele is associated with reduced grey
matter volume in the limbic system and disrupted amy-
gdala-cingulate coupling (95).
The intron 2 VNTR contains nine, 10, or 12 copies of
a sixteen- or seventeen-base pair repeat (96). A stronger
expression and greater enhancer activity was observed by
the 12-copy allele than by the 10-copy allele in the hind-
brain of transgenic embryonic mice (97) and in embry-
onic stem cells (98) suggesting its functionality. Very poor
linkage disequilibrium was found between 5HTTLPR
and the intron 2 VNTR (99).
A lot of studies conducted in healthy individuals and
in patients with psychiatric and neurological disorders
suggested that 5-HTTLPR could be considered as a can-
didate gene for depression (99), mood disorders (100), al-
coholism, autism and stress related psychiatric disorders,
while other studies did not replicate these data (101). An
association between early stressful life event (childhood
maltreatment, abuse, lack of social support) and increas-
ing risk for the development of depression in subjects
carrying short alleles was found (102). In addition, there
is a growing body of literature suggesting the connection
between stressful life events and occurrence of depression
that may be dependent on variation at the 5-HTTLPR
locus of the 5-HTT (102). However, recent meta-analysis
(103) did not confirm that the 5-HTTLPR genotype and
stressful life events, alone or in combination, are risk fac-
tors for the development of depression in both male and
female subjects.
Different findings related to the association between
5HTTLPR and psychiatric disorders might be induced
by differences in population genetic structure and sub-
structure between cases and controls, and to ancestry dif-
ferences corresponding to ethnic groups. There are signi-
ficant differences in the allele frequencies in 5-HTTLPR
between Caucasian and Asian populations, since S allele
is found in 42% of Caucasians and in 79% of Asians
(104). In the large groups of healthy subjects from Croa-
tia and the Russian federation (Russians, Bashkirs and
Tatars) there were significant ethnic differences in allele
and genotype frequencies of the 5-HTTLPR (104). The-
se finding might explain the contradictory results show-
ing the positive or negative or no association between
various psychiatric disorders, treatment outcomes and
5-HTTLPR across different populations.
The association between 5HTTLPR and s platelet se-
rotonin concentration was also studied, but the findings
were contradictory, showing positive, negative or a lack of
association (105–107). The study including large groups
of healthy male and smaller groups of female Caucasian
subjects of Croatian origin, free of neuro-psychiatric dis-
orders, showed also a lack of association between 5-
-HTTLPR genotypes and platelet 5-HT concentration,
and failed to detect the functional relevance of the 5-
-HTTLPR variants on platelet 5-HT concentration (107).
Therefore, since a positive significant association be-
tween L/L and L/S genotypes and increased blood sero-
tonin levels was detected in patients with obsessive-com-
pulsive disorder, the results of the lack of association be-
tween 5HTTLPR and platelet serotonin concentration
suggest that genotype-induced changes in 5-HTT tran-
scription and consequent changes in platelet serotonin
concentration might be differently regulated in healthy
subjects and psychiatric patients (107).
The relationship between the changes in serotonin
uptake and 5-HTT gene in patients with AD is inconsis-
tent. A study (108) failed to find the difference in the
allelic distribution on the deletion/insertion polymor-
phism of the 5-HTT gene between patients and controls.
In contrast, an association between long allele of the
5-HTT gene and development of aggressive behaviour
in AD was found (109).
Serotonin type 1A receptor
Serotonegic receptor type 1A (5-HT1A) is one of the
most investigated and characterized serotonergic recep-
tors. The 5-HT1A receptors were found in a variety of
human brain regions (110). They are subdivided accord-
ing to their location in a) presynaptic somatodendritic
5-HT1A autoreceptors located on cell bodies and den-
drites of serotonergic neurons in dorsal and median ra-
phe nuclei and b) 5-HT1A heteroreceptor positioned
postsynaptically in the pyramidal cells and interneurons
of cortico-limbic regions (hippocampus, cerebral cortex
and lateral septum) that received serotonergic input from
the raphe nuclei (5). The activation of presynaptic 5-HT1A
autoreceptors by serotonin or its agonists inhibits the fir-
ing rate of the serotonergic neuron and reduces serotonin
synthesis, turnover and release (111) and thus affects the
serotonergic activity in projection areas. In addition,
5-HT1A receptors have an important role in the neuro-
developmental processes such as synapse formation, neu-
rite outgrowth and neuronal migration (112). Due to
their wide distribution and multitude of functions, 5-
-HT1A receptors are associated with aetiology and treat-
ment of mental disorders (113), especially major depres-
sive disorder.
Post-mortem evaluation of the number and/or affinity
of 5-HT1A receptors in the brain of depressed patients
revealed different results among studies. Reduced 5-HT1A
ligand binding or receptor gene expression was found in
cortico-limbic regions of the suicide depressed victims
with or without medication at the time of death (114).
The increase in 5-HT1A receptor binding (115) and
negative results (116) were also reported. This lack of
consistency between studies can be due to the variety of
factors including sex, comorbidities (substance abuse, al-
cohol dependence and other psychiatric diagnoses),
post-mortem delay and to the different methods used for
the measurement of the 5-HT1A ligand binding. The
desensitization of presynaptic 5-HT1A autoreceptors,
but not postynaptic receptors was observed after chronic
treatment with antidepressants like serotonin reuptake
inhibitors and monoamine oxidase inhibitors.
The 5-HT1A receptor is coded by the HTR1A gene
(OMIM *109760) located on chromosome 5 at position
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5q11.2-q13. Recently, the 27 single nucleotide polymor-
phisms of the HTR1A gene were described (113). Among
them the most investigated, and the most prevalent in
normal human population is a functional polymorphism
C-1019G (rs6295), located within the promoter region of
the gene. It has been shown that this polymorphism reg-
ulates gene expression (117). Genetic studies suggested
that the G allele of the C-1019G is associated with an in-
crease in presynaptic 5-HT1A receptor expression and
lowered expression of the postsynaptic 5-HT1A receptor.
These opposite effects could be related to two transcrip-
tion factors: epidermal autoregulatory factor-1 (Deaf-1
or NUDR) and Hes5 that are co-localized on both, pre-
synaptic and postsynaptic 5-HT1A receptors (117, 118).
Deaf-1 is a repressor at somatodendritic 5-HT1A recep-
tor, but enhances the transcription in non-serotonergic
neurons that express postsynaptic 5-HT1A receptors.
Several studies investigated the association between
C-1019G HT1A promoter polymorphism and regional
binding potential of two selective 5-HT1A antagonists
11C-WAY100635 or 18F-MPPF using Positron Emission
Tomography (PET) in healthy subjects, but with incon-
sistent results (119). Concerning response to treatment,
the C-1019G variant seems to be of primary interest in
antidepressant response: C allele carriers generally show
a better response to treatment, especially in Caucasian
samples (113).
Serotonin type 1B receptor
Serotonergic receptors type 1B (5HT1B) were found
to be rodent specific and similar to the human seroto-
nergic receptor type 1D (5-HT1D). Since these two ty-
pes of 5-HT1 receptors share similar brain distribution,
transductional features and function, it has been sug-
gested that they are species homologues with 97% overall
sequence homology (5).
Serotonergic receptors type 1B (5HT1B) are terminal
autoreceptors and postsynaptic heteroreceptors (5), lo-
cated in the central nervous system in the basal ganglia,
striatum, hippocampus and cortex. 5-HT1B receptors
were also found on the variety of vascular tissues includ-
ing cerebral arteries. The main function of autoreceptors
located on the nerve terminals is the control of serotonin
release, but they may act as terminal heteroreceptors con-
trolling the release of other neurotransmitters like cate-
cholamine and GABA (5).
A recent study (120) has shown the co-localization
and interaction of 5-HT1B receptors and protein p11 at
the cell surface in vitro. The p11 knockout mice exhib-
ited a depression-like phenotype and had reduced re-
sponsiveness to 5HT1B receptor agonists and reduced
behavioural reactions to antidepressants. The decrease in
brain p11 expression was found in the animal model of
depression and in the brain tissue from depressed pa-
tients, while an over expression in p11 and the increase in
5HT1B receptor function was observed in rodent brains
after antidepressants or electroconvulsive therapy (120).
Animal studies suggested that 5-HT1B receptors ha-
ve a role in aggressive behaviour related to alcoholism.
Knockout mice showed increased alcohol intake and
more propensities to aggressive behaviour, although ot-
her studies (121) did not confirm the relationship be-
tween 5-HT1B receptors and alcoholism. The 5-HT1B
receptor gene has been postulated to play a modulatory
role in alcohol consumption and alcohol dependence,
and was considered as candidate gene for alcoholism
(122).
In humans 5-HT1B receptor is encoded by the gene
HTR1B (OMIM*182131) located on chromosome 6 wi-
thin the region 6q13-q26 at position 6q14.1. Intronless
HTR1B gene consists of a single exon, encoding a 390
amino acid peptide (123). A number of polymorphisms
has been discovered in the coding sequence and sur-
rounding 5’ and 3’ untranslated regions. 5HTR1B gene is
an attractive candidate for studies of the genetic basis of
ADHD (124). The most widely studied polymorphism
of the HTR1B gene in and around the HTR1B locus is
relatively common synonymous G861C polymorphism
(124).
Serotonin type 2A receptor
Serotonin type 2A receptor (5HT2A) is a G protein
coupled serotonergic receptor located on the membrane
of postsynaptic serotonergic neurons. High concentra-
tions of 5-HT2A receptors were found on the apical den-
drites of pyramidal cells in layer V in cortex (prefrontal,
parietal, somatosensory), claustrum and basal ganglia (5).
In the brain 5-HT2A receptors mediate hormone secre-
tion, mood and perception, and regulate different behav-
iours. 5-HT2A receptors are highly expressed in blood
platelets, fibroblasts, and many cell types of the cardio-
vascular system. Widely distributed peripheral 5-HT2A
receptors are involved in the platelet aggregation (14),
capillary permeability and vascular smooth muscles con-
traction. 5-HT2A receptors are molecular target for many
atypical antipsychotic drugs like olanzapine or risperidone.
The loci encoding the serotonin type 2A receptor
(HTR2A) are located on the long arm of the chromo-
some 13q14-q21 in man, and on chromosome 14 in the
mouse (125). The HTR2A gene consists of 3 exons sep-
arated by 2 introns and spans over 20 kb (126). A num-
ber of polymorphisms encoding for HTR2A gene was
found, including A-1438G (rs6311), T102C (rs6313)
and His452Tyr (rs6314). Several genetic studies investi-
gated the association of HTR2A genetic variants and vul-
nerability to psychiatric disorders like schizophrenia (127),
suicide (128), panic disorder, alcoholism (129) and AD
(130), with inconsistent and mostly negative results. Sev-
eral studies reported that particular polymorphism in
HTR2A gene may, to some extent, account for the differ-
ence in treatment response to risperidone (131), cloza-
pine (132) and antidepressants (133).
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IN CONCLUSION
Since serotonin discovery in the gastrointestinal tract
(1), the comprehensive investigations enlarge its first role
as a hormone to the neurotransmitter function in the
central nervous system that has a myriad of central and
peripheral functions. However, serotonin has an impor-
tant role in the modulation the effects of other neuro-
transmitters. In the words of Thomas Carew, a Yale re-
searcher, »Serotonin is only one of the molecules in the
orchestra. But rather than being the trumpet or the cello
player, it is the band leader who choreographs the output
of the brain.«
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